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Determinants of Fasting and Post-Methionine Homocysteine
Levels in Families Predisposed to Hyperhomocysteinemia
and Premature Vascular Disease
S.C. de Jong, C.D.A. Stehouwer, M. van den Berg, P.J. Kostense, D. Alders, C. Jakobs,
G. Pals, J.A. Rauwerda
Abstract—Elevated plasma total homocysteine (tHcy) levels, either measured in the fasting state or after oral methionine
loading, are associated with an increased risk of atherothrombotic disease. Fasting and post-methionine hyperhomo-
cysteinemia (HHC) overlap to a limited extent; both can occur as familial traits. We investigated determinants of fasting,
postmethionine and delta (ie, post-methionine minus fasting levels) tHcy levels in 510 subjects of 192 HHC-prone
families including 161 patients with clinical vascular disease and 349 without vascular disease. We focused on tHcy
levels in relation to levels of vitamin B12, B6 and folate and the methylenetetrahydrofolate reductase (MTHFR)
C677T mutation. Multivariate linear analyses adjusted for the presence of vascular disease showed that fasting tHcy was
significantly related to folate and vitamin B12, and the presence of the MTHFR TT genotype and the T allele, and to age,
smoking habits, and serum levels of creatinine. Both post-methionine and delta tHcy levels were related to serum folate
levels, and the presence of the MTHFR TT genotype and the T allele, and to postmenopausal status, and body mass
index. An interaction was found between MTHFR TT genotype and serum folate levels for both fasting and
post-methionine tHcy, ie, for a given decrease in serum folate, homocysteine levels increased more in subjects with the
TT genotype than in those with the CC genotype. Fasting, post-methionine and delta tHcy were higher in patients with
vascular disease than in their healthy siblings, but these levels were less dependent on serum folate levels (P,0.05),
whereas the effect of MTHFR genotype was stronger (P50.01). This study found evidence that post-methionine and
delta tHcy levels are not only influenced by factors affecting homocysteine transsulfuration but also by factors that affect
remethylation. The explained variances of fasting, post-methionine and delta tHcy were 49%, 62%, and 78%,
respectively. We also found evidence, in patients with premature vascular disease but not in their healthy siblings, for
a factor that increases tHcy levels but weakens the normal inverse relation between folate and tHcy and amplifies the
effect of the MTHFR genotype. (Arterioscler Thromb Vasc Biol. 1999;19:1316-1324.)
Key Words: homocysteine n methionine loading test n methylenetetrahydrofolate reductase n vitamins
n familial hyperhomocysteinemia n premature vascular disease
Elevated plasma total homocysteine (tHcy) levels, eithermeasured in the fasting state or after oral methionine
loading, are associated with an increased risk of atherothrom-
botic disease.1–4 Fasting and post-methionine hyperhomocys-
teinemia (HHC) overlap to a limited extent,3,5–8 so that it is of
interest to gain more insight in the determinants of both
fasting and post-methionine tHcy levels.
Important factors governing homocysteine levels are fo-
late, vitamin B12 and vitamin B6 status, and homozygosity for
the C677T mutation of the methylenetetrahydrofolate reduc-
tase (MTHFR) gene.3,9–23 Except for vitamin B6, these
variables are thought to be involved in homocysteine re-
methylation and thus to be associated specifically with the
fasting rather than the post-methionine level, the latter being
thought to reflect (vitamin B6-dependent) homocysteine
transsulfuration.24 Recently, fasting tHcy levels have in ad-
dition been shown to be positively correlated with male sex,
age, smoking, blood pressure and serum levels of cholesterol
and creatinine.25
Both fasting and post-methionine HHC can occur as
familial traits.6,26–29 It is not known to what extent vitamin
and MTHFR mutation status determine fasting and post-
methionine tHcy levels in families in which HHC is preva-
lent. The first aim of this study, therefore, was to investigate
this in 510 subjects of 192 HHC-prone families.6,7 In addi-
tion, if fasting and post-methionine tHcy do indeed reflect
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homocysteine remethylation and transsulfuration, respec-
tively, it can be hypothesized that the determinants of
post-methionine tHcy differ from those of fasting tHcy, but
this has not been extensively studied.30 The second aim of this
study thus was to investigate this by comparing the determi-
nants of fasting with those of post-methionine tHcy. Because
the level after methionine loading will, to at least some
extent, be influenced by the fasting level, we also studied the
delta homocysteine level, ie, the post-methionine minus the
fasting level.5
Subjects and Methods
Subjects
In April 1993, we started a HHC screening program among consec-
utive patients with clinically manifest arterial occlusive disease with
onset before the age of 55 years. Definitions of vascular disease have
been described in detail elsewhere.6
From April, 1993, to January, 1995, we screened 737 patients. We
then randomly selected 192 patients for family studies, with '3:1
oversampling of patients with versus those without HHC after a
methionine loading test, as described below. We here report on 510
subjects from 192 different families. Of these 510 subjects, 161 had
clinical vascular disease (patients) and 349 did not (healthy siblings).
In 31 families the index patient could not be studied. Of the 161
patients, 122 (76%) had post-methionine HHC. Subjects (n520)
using multivitamin supplementation or folic acid, vitamin B12 or
vitamin B6 were asked to stop this for at least 5 months before the
methionine loading test.
All subjects underwent a methionine loading test and additional
investigations, as detailed below. All subjects gave informed consent
for this study, which was approved by the local ethics committee.
Methionine Loading Test and
Additional Investigations
After an overnight fast, venous blood samples were taken between 9
and 10 AM according to a strict protocol. Subjects were asked to
refrain from smoking and from using alcohol from 10 PM on the
evening before blood sampling. A second blood sample was obtained
6 hours after an oral methionine load (0.1 g/kg body weight). (One
tHcy measurement after 6 hours is commonly used to obtain a
reasonable if imperfect description of the area under the tHcy curve
after methionine loading.) Plasma was separated immediately after
sampling; samples were stored at 230°C until use. Homocysteine
was determined within 1 week of blood sampling. Total (free plus
protein-bound) homocysteine concentrations were measured by us-
ing tri-n-butylphosphine as the reducing agent and ammonium
7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate as the fluorochro-
mophore, followed by high-pressure liquid chromatography with
fluorescence detection.31 Reference values for fasting and post-
methionine homocysteine in our laboratory are ,18 and
,54 mmol/L, respectively, in men, ,15 and ,51 mmol/L, respec-
tively, in premenopausal women, and ,19 and ,69 mmol/L,
respectively, in postmenopausal women. (These reference values
were obtained from a group of healthy volunteers recruited from the
hospital staff who had vitamin B6, B12, and folic acid concentrations
within the reference ranges. The mean ages [SD] for men [n523]
and women [n541 pre- and n527 postmenopausal women] were
36.9 [5.7] and 42.3 [9.5], respectively.) Delta homocysteine was
defined as the post-methionine minus the fasting homocysteine level.
Just before the methionine loading test, venous blood samples
were taken for measurement of serum levels of folate (radioassay,
Becton Dickinson; reference, .3.4 nmol/L), vitamin B12 (radioassay,
Becton Dickinson; reference, .80 pmol/L) and vitamin B6 (mea-
sured as pyridoxal-5-phospate by high-pressure liquid chromatogra-
phy with fluorescence detection after precolumn derivatization with
semicarbazide; reference, .17 nmol/L).32 We also measured serum
creatinine levels (modified Jaffe´ reaction) and serum lipids (total and
high density lipoprotein [HDL] cholesterol and triglycerides [enzy-
matically]). Low density lipoprotein [LDL] cholesterol was calcu-
lated by Friedewald’s formula.33
For the C677T MTHFR mutation analysis, DNA was obtained
from the buffy coat of EDTA blood. The mutation creates a HinfI
restriction site, which was used for analysis. The polymerase chain
reaction (PCR) conditions and the sequence of the primers used in
the amplification of the part of the gene containing the mutation were
taken from Frosst et al.15 HinfI restriction enzyme analysis of the
PCR products and subsequent electrophoresis in a 3% agarose gel
were used to determine the mutation status of the subject, with TT,
CT, and CC indicating subjects homozygous and heterozygous for
the mutation and homozygous for the wild type, respectively.
At the time of blood sampling we recorded age, body weight and
height, menopausal status (post-menopause was defined as absence
of menstrual bleeds for .1 year), presence of hypertension (WHO
criteria), and current and past smoking habits. Body mass index was
calculated as weight/height.2
Statistical Analysis
Data were analyzed with the statistical package SPSS for Windows
6.1. Descriptive data are given as mean (SD) or, when skewed, as
median (range). The distributions of homocysteine levels were
skewed with a long tail toward high values. Log-transformed
homocysteine values were therefore used in the linear regression
analyses and the results were transformed back to the orginal scale.
Our main interest was the relation between tHcy levels on the one
hand and serum levels of folate, vitamin B12 and vitamin B6, and
MTHFR genotype, on the other. We analyzed this in 3 steps. We first
did preliminary analyses adjusted only for age and sex, and, because
of the selection procedure (see above), for the presence of vascular
disease. We next investigated possible confounding variables: meno-
pausal status, body mass index, smoking habits, pack years (calcu-
lated by multiplying the number of cigarette packages smoked per
day by the number of years the subject smoked), the presence of
hypertension, serum lipids and serum creatinine. Third, to examine
whether relationships between various determinants of plasma ho-
mocysteine concentrations were independent of each other, we
entered all variables that had a P value of ,0.2 in the preliminary
analyses into an extended multivariate linear model, except for the
presence of vascular disease and serum vitamin levels, which were
entered into all extended multivariate analyses. Relative changes in
homocysteine levels per the indicated change in the independent
variables (ie, back-transformed regression coefficients) are given
with their 95% confidence intervals (CIs). The MTHFR genotype
was entered into the regression models in 2 different ways (one at a
time): taking CC as the reference category, we studied either the
contrast between TT and CC or that between CT and CC. Further-
more, we investigated the presence of possible interactions among
vitamin levels, MTHFR genotype and presence of vascular disease
by adding the appropriate interaction terms to the extended multi-
variate models.
All testing was 2-tailed with 0.05 as the level of significance.
Results
Table 1 shows characteristics of the study population. The
distribution of the C677T polymorphism of the MTHFR gene
in our study population followed the Hardy-Weinberg equi-
librium (data not shown). As expected, the oversampling of
patients with versus those without post-methionine HHC
resulted in higher fasting, post-methionine and delta tHcy in
the patients than in the siblings (all P values ,0.0001). They
also had a higher prevalence of the MTHFR T allele (72.7%
versus 62.8%; P50.03), but not of the TT genotype (19.4%
versus 16.7%; P50.45), and were older and were more often
smokers, had a higher number of pack years, higher serum
levels of creatinine, cholesterol and triglycerides, and lower
serum levels of HDL cholesterol, folate, vitamin B12 and
vitamin B6 (data not shown).
Fasting Homocysteine Level
The extended multivariate analyses showed that fasting tHcy
levels were significantly related to folate and vitamin B12, the
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presence of the MTHFR TT genotype and the T allele, patient
status, and to age, current smoking, pack years, and serum levels
of creatinine (Table 2). When we repeated this analysis with
exclusion of folate and vitamin B12, fasting homocysteine levels
were not related to vitamin B6 (relative change per 30 nmol/L
increase of vitamin B650.999; CI, 0.998 to 1.0004, P50.19).
Post-Methionine Homocysteine Level
Post-methionine and delta tHcy were related to serum folate
levels, the presence of the MTHFR T allele and the MTHFR
TT genotype, patient status, and to postmenopausal status,
and body mass index. When we repeated the extended
multivariate analysis with exclusion of folate, post-
methionine tHcy was related to vitamin B6 (relative change
per 30 nmol/L increase of vitamin B650.96; CI, 0.92 to 0.99,
P50.03). Delta tHcy was related to vitamin B6 after exclusion
of both vitamin B12 and folate (relative change50.95; CI,
0.90 to 0.99, P50.05). We repeated the extended multivariate
analyses for post-methionine tHcy by adding fasting tHcy to
the model, which gives a more precise adjustment for the
influence of fasting on post-methionine tHcy than studying
delta tHcy. The results were similar, except that the relations
with the presence of the MTHFR T allele and TT genotype
were no longer significant (relative change51.06; CI, 0.98 to
1.15, P50.17 for the T allele and 51.11; CI, 0.97 to 1.26,
P50.13 for the TT genotype).
We repeated all analyses after exclusion of subjects with
tHcy .60 mmol/L fasting (n58), .120 mmol/L post-
methionine (n514), and/or .105 mmol/L delta (n510). The
results were similar (data not shown).
Interaction Analyses
We next studied the possibility of an interaction between
MTHFR genotype and folate status on tHcy levels.12 For both
fasting and post-methionine tHcy levels, the interactions
between serum folate levels and MTHFR TT were significant.
For each 10-nmol/L decrease in folate levels, fasting and
post-methionine tHcy increased with factors of 1.16 and 1.11
in subjects with the CC and with factors of 1.74 and 1.31 in
those with the TT genotype (P50.0001 and 50.003, Table 3,
Figure 1A and 1B). For delta tHcy, the interaction between
TT genotype and folate status was not significant, although
the point estimates were similar to those of post-methionine
tHcy (Table 3). Interactions between CT genotype and serum
folate levels were not significant for any tHcy level (Table 3).
We next found, for fasting, post-methionine and delta
tHcy, an interaction between the presence of vascular disease
and serum folate. In healthy siblings, each 10-nmol/L de-
crease of folate levels raised fasting, post-methionine and
delta tHcy with, respectively, a factor of 1.36 (CI, 1.24 to
1.46), 1.29 (CI, 1.19 to 1.39), and 1.22 (CI, 1.11 to 1.34), as
compared with a factor of 1.06 (CI, 1.01 to 1.14), 1.06 (CI,
1.001 to 1.12), and 1.004 (CI, 1.001 to 1.006) in patients
(P,0.05 for all interactions; Figure 2A and 2B).
For post-methionine tHcy, we also found an interaction
between serum vitamin B12 levels and presence of vascular
disease. For each 30-pmol/L decrease in vitamin B12, post-
methionine tHcy increased with a factor of 1.008 (CI, 1.001
to 1.02) in siblings versus a factor of 1.04 (CI, 1.01 to 1.06)
in patients (P,0.05; Figure 3). For fasting and delta tHcy, the
interactions between serum vitamin B12 levels and presence of
vascular disease were not significant: for each 30-nmol/L
decrease in vitamin B12, fasting and delta tHcy increased with
factors of 1.008 (CI, 1.007 to 1.011) and 0.99 (CI, 0.98 to
1.01) in siblings versus factors of 1.02 (CI, 1.006 to 1.04) and
1.03 (CI, 0.996 to 1.06) in patients (P for interaction 50.37
and 50.10, respectively).
Finally, we found an interaction between the presence of
the TT genotype and the presence of vascular disease with
respect to tHcy. Among those with the TT genotype, fasting
tHcy was a factor of 1.39 higher in patients compared with
TABLE 1. Laboratory and Clinical Characteristics of 510
Subjects From 192 Families With an Index Patient With
Premature Arterial Occlusive Disease
n (%), M/F 249 (48.8)/261 (51.2)
Postmenopausal state, n (% women) 82 (31.4)*
Age, y 44.569.7
Preexisting vascular disease, n (%) 161 (31.6)
Plasma homocysteine in the entire population,
(mmol/L)†
Fasting 11.4 (7.2, 8.9, 15.3, 21.8)
Post-methionine 51.6 (29.8, 36.7, 68.0, 88.3)
Delta 36.7 (20.7, 26.2, 49.8, 70.8)
Plasma homocysteine in patients, (mmol/L)‡
Fasting 14.3 (3.3–98.6)
Post-methionine 61.3 (15.5–214.9)
Delta 44.7 (9.6–147.4)
Plasma homocysteine in siblings, (mmol/L)‡
Fasting 10.8 (4.8–174.1)
Post-methionine 42.9 (12.7–196.3)
Delta 31.6 (0.4–133.0)
Current smokers, n (%) 219 (42.9)
Current or past smokers, n (%) 328 (64.3)
Pack years‡§ 17.5 (1.0–98.0)
Body mass index (kg/m2) 25.164.0
Hypertension, n (%) 115 (22.5)
Creatinine (mmol/L) 85.2613.6
Total cholesterol (mmol/L) 6.061.2
HDL cholesterol (mmol/L) 1.360.6
LDL cholesterol (mmol/L) 3.961.1
Triglyceride (mmol/L) 1.761.0
Vitamin B6 (nmol/L)‡ 27.0 (4.0–272.0)
Vitamin B12 (pmol/L)‡ 260.0 (53.0–727.0)
Folate (nmol/L)‡ 11.4 (0.6–93.0)
Methylenetetrahydrofolate reductase, n (%)\
Homozygous normal (CC) 167 (34.1)
Heterozygous mutant (CT ) 237 (48.4)
Homozygous mutant (TT ) 86 (17.6)
T allele carrier 323 (65.9)
Data are given as number (n) with percentages in parentheses or as mean
with SD. Delta homocysteine levels indicate post-methionine levels minus
fasting levels.
*Four postmenopausal women used hormone replacement therapy; †Median
and 10th, 25th, 75th, and 90th percentile; ‡Skewed data are given as median
(range).
§Pack years were calculated by multiplying the number of cigarette
packages smoked per day by the numbers of years the patient smoked.
\In 20 subjects, MTHFR genotype was not available.
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healthy siblings; for the CC genotype, this was 1.19 (P50.01
versus TT; Table 3). For post-methionine and delta tHcy, the
interaction between genotype and patient status was not
significant (Table 3).
To check whether the interactions of (1) MTHFR genotype
with folate, and (2) folate and vitamin B12 with patient status
(see above) were related to the differences in tHcy level
distribution between (1) subjects with the TT and those with
CC genotype, and (2) patients and siblings, we added the
appropriate squared terms of folate and vitamin B12 to the
interaction analyses. The interactions between MTHFR ge-
notype and folate remained significant, as did that between
folate and patient status for fasting tHcy. For post-methionine
and delta tHcy, the interaction between patient status and
folate lost significance, as did that with vitamin B12 for
post-methionine tHcy. However, the squared term was sig-
TABLE 2. Results of Preliminary and Extended Multivariate Linear Analyses of Determinants of Homocysteine Levels Among
510 Subjects
Fasting Post-methionine Delta
Relative Change P Relative Change P Relative Change P
Preliminary multivariate
Folate (per 10 nmol/L) 0.85 (0.81–0.90) ,.0001 0.986 (0.982–0.99) ,.0001 0.90 (0.85–0.96) .001
Vitamin B6 (per 30 nmol/L) 0.97 (0.93–1.01) .18 0.94 (0.91–0.98) .003 0.94 (0.90–0.98) .01
Vitamin B12 (per 30 pmol/L) 0.98 (0.97–0.99) .0002 0.987 (0.975–0.998) .02 0.995 (0.98–1.01) .50
Methylenetetrahydrofolate reductase§
Homozygous normal (CC) 0.80 (0.73–0.88) ,.0001 0.88 (0.82–0.95) .001 0.90 (0.82–0.99) .04
Heterozygous mutant (CT) 1.16 (1.06–1.25) .0008 1.10 (1.01–1.19) .02 1.09 (0.98–1.20) .03
Homozygous mutant (TT) 1.56 (1.39–1.74) ,.0001 1.26 (1.13–1.40) .0001 1.16 (1.003–1.34) .05
T allele carrier 1.24 (1.14–1.36) ,.0001 1.13 (1.05–1.22) .001 1.11 (1.01–1.21) .04
Male sex 1.18 (1.09–1.30) .0001 z z z z z z 0.92 (0.84–1.0005) .05
Postmenopausal state z z z z z z 1.12 (0.995–1.30) .06 1.21 (1.04–1.41) .01
Age (per 1 year) z z z z z z 1.003 (0.999–1.007) .14 1.004 (0.999–1.009) .009
Current smokers (yes/no) 1.10 (1.02–1.20) .02 z z z z z z z z z z z z
Pack years* (per 1) 1.002 (0.999–1.004) .19 z z z z z z z z z z z z
Body mass index (per 1 kg/m2) z z z z z z 1.01 (1.0006–1.02) .04 1.02 (1.01–1.03) .004
Creatinine (per 10 mmol/L) 1.05 (1.01–1.08) .01 z z z z z z z z z z z z
Total cholesterol (per 1 mmol/L) 0.97 (0.93–1.01) .13 z z z z z z 1.03 (0.99–1.08) .17
HDL cholesterol (per 0.1 mmol/L) z z z z z z 0.992 (0.985–0.995) .04 0.992 (0.983–1.0003) .06
LDL cholesterol (per 1 mmol/L) z z z z z z 1.04 (0.995–1.08) .08 1.05 (0.99–1.11) .08
Triglyceride (per 1 mmol/L) z z z z z z 1.03 (0.99–1.08) .14 z z z z z z
Extended multivariate†
Folate (per 10 nmol/L) 0.82 (0.78–0.88) ,.0001 0.85 (0.80–0.90) ,.0001 0.86 (0.79–0.90) .0004
Vitamin B12 (per 30 pmol/L) 0.97 (0.94–0.99) .002 z z z z z z z z z z z z
Methylenetetrahydrofolate reductase‡
Homozygous normal (CC) 0.87 (0.80–0.95) .001 0.89 (0.81–0.97) .009 0.87 (0.78–0.98) .02
Heterozygous mutant (CT ) 1.09 (0.99–1.19) .07 1.08 (0.99–1.19) .10 1.11 (0.97–1.27) .11
Homozygous mutant (TT ) 1.36 (1.22–1.52) ,.0001 1.21 (1.06–1.38) .004 1.28 (1.05–1.56) .02
T allele carrier 1.16 (1.06–1.26) .0011 1.12 (1.02–1.23) .01 1.14 (1.01–1.29) .03
Vascular patient (yes/no) 1.19 (1.07–1.31) .0008 1.24 (1.12–1.38) ,.0001 1.24 (1.09–1.41) .001
Postmenopausal state z z z z z z 1.19 (1.03–1.37) .02 1.25 (1.04–1.50) .02
Age (per 1 year) 1.005 (1.0002–1.01) .04 z z z z z z z z z z z z
Current smokers (yes/no) 1.11 (1.02–1.21) .01 z z z z z z z z z z z z
Pack years* (per 1) 1.003 (1.0006–1.06) .02 z z z z z z z z z z z z
Body mass index (per 1 kg/m2) z z z z z z 1.01 (1.002–1.02) .02 1.02 (1.003–1.03) .02
Creatinine (per 10 mmol/L) 1.05 (1.02–1.1) .005 z z z z z z z z z z z z
Explained variance of the model (%) 49 .0001 62 .05 78 .03
For preliminary analyses, all P,0.2 are shown adjusted for age, sex, and preexisting vascular disease. For the extended analyses, all P,0.05 are shown. Relative
changes in homocysteine level per the indicated change in the independent variable are shown with 95% confidence intervals. (The relative change corresponds to
the antilog of the regression coefficient; see Methods). Delta homocysteine levels indicate post-methionine levels minus fasting homocysteine levels.
*Pack years were calculated by multiplying the number of cigarette packages smoked per day by the numbers of years the patient smoked.
†Adjusted for vitamin B6, B12, and folate and for all variables with P,0.2 in preliminary analyses as shown in the upper part of the table, without interaction terms.
‡In 20 subjects, MTHFR genotype was not available.
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nificant only for the folate-patient interaction with regard to
post-methionine tHcy (data not shown).
When we repeated the interaction analyses for post-
methionine tHcy by adding fasting homocysteine levels to the
models, the results were similar and did not reveal any new
interactions (data not shown).
Discussion
We studied determinants of fasting, post-methionine and
delta tHcy levels in 510 subjects from 192 families in which
both HHC and premature vascular disease are prevalent.6,7
The main findings were twofold. First, fasting, post-
methionine and delta tHcy were all influenced by serum
folate concentrations, by the MTHFR genotype and by the
interaction between these 2 variables (Tables 2 and 3 and
Figure 1). Second, there were intriguing interactions between,
on the one hand, patient status, and, on the other hand, folate
and vitamin B12 levels and MTHFR genotype: the effect of
folate on fasting, post-methionine and delta tHcy was less
strong in the patients than in their healthy siblings, whereas,
in contrast, the effects of vitamin B12 levels and that of the
MTHFR genotype on post-methionine tHcy were stronger
(Figures 2 and 3).
We made these observations in a group of subjects with, by
design, a high prevalence of high tHcy levels and thus of the
TT genotype.9,17–19,21,34–37 For example, 44%, 73%, and 73%
had fasting, post-methionine and delta tHcy levels .12, 38,
and 27 mmol/L, respectively (ie, the upper quintiles in a
recent large study).3 Our study design thus was very efficient
with respect to the investigation of determinants of high tHcy,
but it must be emphasized that the prevalences of hyperho-
mocysteinemia and its determinants that we observed cannot
be extrapolated to the general population. On the other hand,
there is no a priori reason to believe that this selection
procedure should bias the interrelationships between tHcy
level and its determinants. Thus it is likely that our findings
can in this respect be extrapolated to the general population
and thus are broadly relevant to the study of the determinants
of cardiovascular risk.
Fasting Homocysteine Level
Our findings on fasting tHcy, especially its relation with
serum levels of folate and vitamin B12, the MTHFR genotype,
and the interaction between folate and TT genotype, are in
accordance with previous studies.11,12,14,21,25,34,38 In addition,
fasting tHcy was slightly higher among subjects with the CT
than among those with the CC genotype, which together with
other data34 raises the possibility that heterozygosity for the
C677T mutation of the MTHFR gene may have some effect
on fasting tHcy. Fasting tHcy was not related to postmeno-
pausal status, which is in agreement with Andersson et al38
but not with others.40,41 Fasting tHcy was also not related to
vitamin B6 levels, which contrasts with previous find-
ings.3,39,42,43 These studies,3,39,42 however, except one,43 did
not adjust the effect of vitamin B6 for that of vitamin B12 and
folate.
Post-Methionine Homocysteine Level
Post-methionine tHcy was related to folate levels, the
MTHFR genotype and the postmenopausal state, in agree-
ment with previous data,1,14,15,34,35,41 but the present study is
the first to show that the effect of the TT genotype increased
with decreasing folate levels, ie, that there was an interaction
similar to that for fasting tHcy (Figure 1). Moreover, these
relations were of similar magnitude as those with fasting tHcy
(Table 2). Post-methionine tHcy, in addition, was inversely
related to vitamin B6 levels, but this disappeared after further
adjustment for folate (Table 2). This finding contrasts with
previous studies38 but supports others,39,44 but it must be
noted that the analyses in these studies38,39 were not adjusted
for folate and vitamin B12.
TABLE 3. Interactions for Fasting, Post-Methionine, and Delta (ie, Post-Methionine Minus
Fasting Homocysteine Levels) Homocysteine Levels Between MTHFR Genotypes and Serum
Folate Levels and Patient Status, Respectively
MTHFR Genotype
P† P‡CC CT TT
Folate*
Homocysteine levels (mmol/L)
Fasting 1.16 (1.04–1.29) 1.10 (1.03–1.16) 1.74 (1.43–1.96) .0001 .18
Post-methionine 1.11 (1.01–1.22) 1.10 (1.01–1.16) 1.31 (1.25–1.47) .003 .58
Delta 1.11 (0.96–1.27) 1.12 (1.07–1.19) 1.34 (1.09–1.64) .13 .90
Patient status§
Homocysteine levels (mmol/L)
Fasting 1.19 (1.02–1.38) 1.07 (1.03–1.40) 1.39 (1.24–2.10) .01 .40
Post-methionine 1.22 (1.01–1.48) 1.15 (1.04–1.40) 1.29 (1.12–1.67) .30 .10
Delta 1.22 (1.06–1.42) 1.14 (0.98–1.44) 1.03 (0.91–1.23) .83 .24
Relative change (95% confidence intervals) in homocysteine level per 10 nmol/L decrease of serum folate level*
(upper part) and for patients vs sibling status§ (lower part). (The relative change corresponds to the antilog of the
regression coefficient; see Methods.)
*Per 10 nmol/l decrease of serum folate levels.
†P value for interaction indicating subjects with TT versus subjects with CC genotype.
‡P value for interaction indicating subjects with CT versus subjects with CC genotype.
§Interaction comparing those with (patients) with those without (siblings) vascular disease.
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Figure 1. A, Relation between fasting homocysteine levels (log
scale) and folate levels for subjects with the MTHFR CC geno-
type (top) and for those with the TT genotype (bottom). B, Rela-
tion between post-methionine homocysteine levels (log scale)
and folate levels for subjects with the MTHFR CC genotype
(top) and for those with the TT genotype (bottom).
Figure 2. A, Relation between fasting homocysteine levels (log
scale) and folate levels for subjects without (top) and for those
with vascular disease (bottom). B, Relation between post-
methionine homocysteine levels (log scale) and folate levels for
subjects without (top) and for those with vascular disease
(bottom).
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The investigation of the determinants of post-methionine
tHcy is complicated by the fact that post-methionine tHcy, to
some extent, depends on fasting levels. We dealt with this in
2 ways: by studying delta tHcy and by adjusting the multi-
variate analyses of post-methionine tHcy for fasting levels.
The results of these analyses largely confirmed the initial
analyses with post-methionine tHcy as dependent variable
(Table 2).
Fasting and post-methionine (or delta) tHcy levels are
thought to reflect homocysteine remethylation and transsul-
furation, respectively.24,45,46 Our data on folate, vitamin B12
and MTHFR genotype, all of which affect remethylation, and
fasting tHcy are in accordance with this view, but those on
post-methionine (or delta) tHcy apparently are not. On the
other hand, previous work has convincingly demonstrated
that both vitamin B6 and cystathionine-b-synthase deficiency,
which are primary factors affecting transsulfuration, do lead
to increased post-methionine tHcy.46,47 Taken together,
these46,47 and the present findings thus strongly suggest that
post-methionine and delta tHcy are influenced not only by
factors that affect transsulfuration, but also by factors that
affect remethylation. This hypothesis needs further investiga-
tion, eg, with kinetic modeling of methionine metabolism by
infusion of labeled methionine.48
The Effect of Patient Status
A final intriguing finding was that the effect on tHcy of
folate, vitamin B12, and the TT genotype differed between
patients and healthy siblings. We cannot fully exclude that the
higher tHcy levels in the patients play a role. Nevertheless,
taken together, these data raise the possibility of the presence,
in the patients but not in their healthy siblings, of a factor that
increases tHcy, weakens the normal inverse relation between
folate and tHcy, and, to some extent, amplifies the effects of
vitamin B12 and of the TT genotype on post-methionine tHcy.
The most parsimonious hypothesis is that this reflects a factor
affecting homocysteine remethylation, such as an additional
mutation in the MTHFR gene or a mutation in the methionine
synthase gene. The clinical implication of this finding is that
any such factor may also be linked to vascular disease. These
hypotheses require further investigation.
Study Limitations
The explained variances of fasting, post-methionine and delta
tHcy were 49%, 62%, and 78% respectively (Table 2). Other
determinants thus must play a role,49 which we did not assess.
In addition, we used serum creatinine, an imprecise estimate
of renal function. Nevertheless, we adjusted for many other
variables (Table 2), so important residual confounding ap-
pears unlikely. Moreover, we found that exclusion of subjects
with very high tHcy levels did not materially affect our
results. As noted above, it is plausible that our findings on the
determinants of tHcy can be extrapolated to the general
population, but we cannot fully exclude bias. In any case, our
results are relevant for patients with premature atherothrom-
botic disease and their families. Finally, we assumed that low
folate levels cause an increase in tHcy, but our study was
cross-sectional, so we cannot exclude that, to some degree, a
high tHcy level is a marker of processes that decrease serum
folate.50,51
Conclusions
Fasting, post-methionine and delta tHcy were all influenced
by serum folate concentrations, by the MTHFR genotype and
by the interaction between these 2 variables, suggesting that
post-methionine and delta tHcy are influenced not only by
factors that affect transsulfuration but also by factors affect-
ing homocysteine remethylation. Furthermore, we found
some evidence, in the patients with premature vascular
disease but not in their healthy siblings, for a factor that
increases homocysteine levels but weakens the normal in-
verse relation between folate and homocysteine and amplifies
the effect of the MTHFR genotype. Whether these latter
findings are related to the development of vascular disease
needs further investigation.
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